Acurx Pharmaceuticals, Inc. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 22/100
What the filing says
Acurx Pharmaceuticals amended its bylaws on October 29, 2026, reducing the quorum threshold for stockholder meetings from an unspecified prior level to one-third of voting power outstanding. The change applies to both general meetings and separate class votes. This is a procedural governance modification with no direct financial impact.
Why this rating
Pure governance amendment; routine but reduces barrier to shareholder action. Immaterial to $13.7M market cap company's operations or financial performance.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.